SkinBioTherapeutics (LSE:SBTX) has taken a major step into mainstream retail by securing an exclusive partnership with UK high street giant Superdrug for its AxisBiotix™ line of products. This agreement marks a key commercial milestone as the company expands its footprint beyond direct-to-consumer channels.
To fuel this expansion and advance product development, the company has successfully raised £4.1 million through a combination of share placing and subscriptions. In addition, SkinBioTherapeutics is planning a retail offer aimed at giving existing shareholders a chance to participate in the fundraising.
The AxisBiotix-Ps supplement recently earned the National Psoriasis Foundation’s Seal of Recognition in the United States—an endorsement that is likely to boost its credibility and appeal within the American market.
Despite recent progress, SkinBioTherapeutics continues to face financial challenges, including net losses and cash flow limitations. Technical analysis reflects a bearish trend, and valuation remains pressured by negative earnings. Nevertheless, the recent business developments may signal a turning point, offering a more optimistic outlook for the future.
About SkinBioTherapeutics
SkinBioTherapeutics plc is a biotechnology company focused on improving skin health, particularly through solutions targeting inflammatory skin conditions. The firm’s flagship products, including the AxisBiotix™ range of food supplements, are part of its broader strategy to deliver innovative, science-backed skincare solutions to global markets.
Leave a Reply